- Home
- MDCX vs COEP Comparison
MDCX vs COEP Comparison
Compare MDCX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | COEP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MDCX | COEP |
|---|---|---|
| Price | $1.51 | $14.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 363.3K | 115.0K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.49 | $2.31 |
| 52 Week High | $8.94 | $21.41 |
Technical Indicators
Market Signals| Indicator | MDCX | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 45.11 |
| Support Level | $1.68 | $13.61 |
| Resistance Level | $2.03 | $15.53 |
| Average True Range (ATR) | 0.19 | 1.09 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 5.19 | 37.30 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.